GLP-1 receptor agonists represent one of the most significant developments in metabolic research. These compounds mimic or enhance the action of incretin hormones, which regulate blood sugar and appetite.
Tirzepatide is a dual GIP/GLP-1 receptor agonist. By targeting both receptors simultaneously, it achieves effects on glucose regulation and body weight that may exceed those of single-target agonists.
Retatrutide is a next-generation triple agonist targeting GIP, GLP-1, and glucagon receptors. The addition of glucagon receptor activity is hypothesized to increase energy expenditure and fat oxidation.
Other compounds in this class include survodutide (glucagon/GLP-1 dual agonist), mazdutide, and cagrilintide (long-acting amylin analog often studied in combination with semaglutide).
Research is advancing rapidly. Researchers should ensure they source from suppliers providing verified purity via HPLC and mass spectrometry analysis.
Disclaimer: This article is for educational purposes only. All peptides are sold for laboratory research use only. Not for human consumption.